Last updated: 07/17/2024 17:09:30
This product has been transferred to Emergent BioSolutions. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly with Raxibacumab (GSK3068483)
Trial description: This study, as a post-marketing commitment to the Food and Drug Administration, is designed to detect the effect of raxibacumab on anthrax vaccine adsorbed (AVA) immunogenicity in a healthy volunteer population. This is a randomized, open-label, parallel group, two arm study to compare the immunogenicity of AVA at 4 weeks after the first AVA dose, when AVA is administered alone or concomitantly with raxibacumab. The study is planned to enroll approximately 30 to 534 subjects in up to 3 cohorts. The total duration of the study will be approximately 26 weeks. The dates reflect cohort 1.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Ratio of geometric mean concentrations (GMC) of anti-protective antigen (PA) antibody (Ab) at 4 Weeks (Day 29) after the first AVA dose (prior to the third AVA dose), between the AVA alone and the AVA with raxibacumab treatment groups
Timeframe: Day 29
Secondary outcomes:
Ratio of GMC of anti-PA Ab at Weeks 8 and 26 (Days 57 and 183) after the first AVA dose, between the AVA alone and AVA with raxibacumab treatment groups
Timeframe: Days 57 and 183
Percentage of participants who seroconvert, at Weeks 4, 8, and 26 (Days 29, 57 and 183) after the first AVA dose, between the AVA alone and the AVA with raxibacumab treatment groups
Timeframe: Days 29, 57 and 183
Number of participants with any Serious Adverse Event (SAE) and any non-serious Adverse Event (AE)
Timeframe: Up to Day 183
Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Indicated Time Points
Timeframe: Baseline and up to Day 183
Change from Baseline in heart rate at Indicated Time Points
Timeframe: Baseline and up to Day 183
Change from Baseline in respiratory rate at Indicated Time Points
Timeframe: Baseline and up to Day 183
Change from Baseline in temperature at Indicated Time Points
Timeframe: Baseline and up to Day 183
Number of participants with hematology parameters outside normal range
Timeframe: Up to Day 57
Number of participants with clinical chemistry parameters outside normal range
Timeframe: Up to Day 57
Number of participants with urinalysis parameters
Timeframe: Day 57
Interventions:
Enrollment:
573
Primary completion date:
2017-03-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Nancy Skoura, Vijayalakshmi Chandrasekaran, William Smith, Jie Wang, Oscar della Pasqua, Anne Yeakey, Julia Billiard, Helen Steel, Lionel Tan. A Randomized, Open-label Study to Evaluate the effect of Raxibacumab on the Immunogenicity of Anthrax Vaccine Adsorbed. Lancet Infect Dis. 2020
Medical condition
Infections, Bacterial
Product
raxibacumab
Collaborators
No
Study date(s)
February 2015 to June 2017
Type
Interventional
Phase
4
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination and laboratory tests
- Men and women between 18 to 65 years of age
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or non-investigational study vaccine/product (pharmaceutical product or device).
- Be a member of the military, a laboratory worker, first responder, health care worker, or otherwise be at higher risk of exposure to anthrax.
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination and laboratory tests
- Men and women between 18 to 65 years of age
- Willing and able to adhere to the procedures stated in the protocol.
- Female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one of the following conditions applies: Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy Postmenopausal defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. Reproductive potential and agrees to follow one of the options listed in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP), from 30 days prior to the first dose of study medication and until after the last dose of study medication and completion of the follow-up visit at Day 183 (at least five terminal half-lives for raxibacumab).
Exclusion criteria:
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or non-investigational study vaccine/product (pharmaceutical product or device).
- Be a member of the military, a laboratory worker, first responder, health care worker, or otherwise be at higher risk of exposure to anthrax.
- History of regular alcohol consumption within 1 month of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- Female planning to become pregnant or planning to discontinue contraceptive precautions before the Day 183 study visit.
- Pregnant (confirmed by a serum or urine hCG test) or lactating female.
- Alanine aminotransferase (ALT) and bilirubin >1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test results at screening or within 3 months prior to first dose of study treatment.
- A positive pre-study drug/alcohol screen.
- A positive test for HIV antibody.
- History of sensitivity to any of the study medications, or components thereof (especially latex and aluminium) or a history of other known drug allergies that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation.
- Have previously been vaccinated against PA.
- Have an anti-PA Ab concentration >2 times the lower limit of quantitation at screening.
- Administration of immunoglobulins not included in this trial and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
- Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
- Chronic administration (defined as more than 14 consecutive days) of systemic immunosupressants or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled, topical and intra-articular corticosteroids are allowed.
- Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 35 days before the first dose of study vaccine(s) and ending 30 days after the last dose of study vaccine. This includes any type of vaccine such as (but not limited to) live, inactivated, and subunit vaccines. Influenza vaccines are permitted after Week 8.
- Subjects must abstain from taking prescription or non-prescription drugs (including vitamins and dietary or herbal supplements), within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication until completion of the follow-up visit, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
Trial location(s)
Location
GSK Investigational Site
Edgewater, Florida, United States, 32132
Status
Study Complete
Location
GSK Investigational Site
Knoxville, Tennessee, United States, 37920
Status
Study Complete
Location
GSK Investigational Site
Overland Park, Kansas, United States, 66211
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
No longer a GSK study
Actual primary completion date
2017-03-01
Actual study completion date
2017-06-06
Plain language summaries
Summary of results in plain language
Available language(s): English
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website